The latest price target for Ikena Oncology (NASDAQ:IKNA) was reported by HC Wainwright & Co. on November 11, 2024. The analyst firm set a price target for $4.00 expecting IKNA to rise to within 12 months (a possible 158.06% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Ikena Oncology (NASDAQ:IKNA) was provided by HC Wainwright & Co., and Ikena Oncology reiterated their buy rating.

There is no last upgrade for Ikena Oncology

The last downgrade for Ikena Oncology Inc happened on May 29, 2024 when Wedbush changed their price target from $8 to $2 for Ikena Oncology Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ikena Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ikena Oncology was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Ikena Oncology (IKNA) rating was a reiterated with a price target of $4.00 to $4.00. The current price Ikena Oncology (IKNA) is trading at is $1.55, which is out of the analyst’s predicted range.